HER2 Breast Cancer Brain Mets Drug

So, there’s this oral med called Tucatinib—it’s mainly used for folks with HER2-positive breast cancer who have brain cancer spreading, y’know? It’s a type of TKI, specifically geared towards that HER2 receptor. Available in two dosage strengths, 50 mg and 150 mg, the recommended daily dose is 300 mg administered twice daily, with each dose taken with food. It’s available as those coated tabs, and each bottle has 60 tabs.

How Tucatinib does its thing? It blocks that HER2 receptor, big deal in cancer cell signaling. By blocking it, it actually stops cancer cells with extra HER2 stuff from growing or spreading. And you can trust its effect and safety—it’s been tested on brain cancer patients with that HER2-positive breast cancer thingy.